This article is an erratum on:
The Landscape of Immunotherapy Resistance in NSCLC
An erratum on
The landscape of immunotherapy resistance in NSCLC
by Frisone D, Friedlaender A, Addeo A and Tsantoulis P (2022) 12:817548. doi: 10.3389/fonc.2022.817548
An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Geneva”.
The original version of this article has been updated.
Keywords: immunotherapy, resistance, checkpoint inhibitor, NSCLC, lung cancer
Citation: Frontiers Production Office (2023) Erratum: The landscape of immunotherapy resistance in NSCLC. Front. Oncol. 13:1187021. doi: 10.3389/fonc.2023.1187021
Received: 15 March 2023; Accepted: 15 March 2023;
Published: 04 April 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn